| Title |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, October 2013
|
| DOI | 10.1038/clpt.2013.203 |
| Pubmed ID | |
| Authors |
A J Muir, L Gong, S G Johnson, M T M Lee, M S Williams, T E Klein, K E Caudle, D R Nelson |
| Abstract |
Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 1% |
| France | 1 | 1% |
| Egypt | 1 | 1% |
| Unknown | 93 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 22 | 23% |
| Student > Ph. D. Student | 14 | 15% |
| Researcher | 12 | 13% |
| Student > Postgraduate | 7 | 7% |
| Professor > Associate Professor | 6 | 6% |
| Other | 23 | 24% |
| Unknown | 12 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 23% |
| Biochemistry, Genetics and Molecular Biology | 15 | 16% |
| Agricultural and Biological Sciences | 15 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 10% |
| Unspecified | 4 | 4% |
| Other | 13 | 14% |
| Unknown | 17 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2018.
All research outputs
#6,480,423
of 22,982,639 outputs
Outputs from Clinical Pharmacology & Therapeutics
#1,438
of 4,211 outputs
Outputs of similar age
#58,268
of 208,314 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#14
of 34 outputs
Altmetric has tracked 22,982,639 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 4,211 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 208,314 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.